Migoya E

ORCID: 0000-0002-7635-4417 · 2 papers in corpus · active 2023

Study types

  • other 1

Condition tags

  • dysmenorrhea 1
  • endometriosis 1
  • dyspareunia 1
2023
A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women.
Clinical pharmacokinetics ·doi:10.1007/s40262-023-01269-9

Background and objectiveRelugolix is a gonadotropin-releasing hormone receptor antagonist. Relugolix 40-mg monotherapy is associated with vasomotor symptoms and long-term bone mineral density loss due to hypoestrogenism. This study assessed…

other 2023
Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis
F&S reports ·doi:10.1016/j.xfre.2022.11.010

Treatment of uterine fibroids (UF) and endometriosis (EM) has relied on the surgical skills of gynecologists to improve symptoms and potentially alter the course of these debilitating diseases. Medical management of symptoms for both diseas…